OA09478A - "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation". - Google Patents

"Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".

Info

Publication number
OA09478A
OA09478A OA59940A OA59940A OA09478A OA 09478 A OA09478 A OA 09478A OA 59940 A OA59940 A OA 59940A OA 59940 A OA59940 A OA 59940A OA 09478 A OA09478 A OA 09478A
Authority
OA
OAPI
Prior art keywords
myristoyl
treatment
phenylalaine
myristoylation
production
Prior art date
Application number
OA59940A
Other languages
English (en)
French (fr)
Inventor
Vincent Michel
Remond Georges
Herve Yolande
Boutin Jean-Albert
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of OA09478A publication Critical patent/OA09478A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA59940A 1990-01-25 1991-01-25 "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation". OA09478A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
OA09478A true OA09478A (fr) 1992-11-15

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59940A OA09478A (fr) 1990-01-25 1991-01-25 "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".

Country Status (14)

Country Link
US (1) US5164414A (enExample)
EP (1) EP0443891B1 (enExample)
JP (1) JPH0717503B2 (enExample)
AT (1) ATE94387T1 (enExample)
AU (1) AU633395B2 (enExample)
CA (1) CA2034861A1 (enExample)
DE (1) DE69100364T2 (enExample)
DK (1) DK0443891T3 (enExample)
ES (1) ES2060310T3 (enExample)
FR (1) FR2657259A1 (enExample)
IE (1) IE65573B1 (enExample)
OA (1) OA09478A (enExample)
PT (1) PT96571A (enExample)
ZA (1) ZA91574B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
US20030022938A1 (en) * 2001-06-25 2003-01-30 Burstein Sumner H. N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
AU2012286542A1 (en) 2011-07-22 2014-02-06 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
US10201175B2 (en) 2012-03-30 2019-02-12 Givaudan Sa N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds
CA2868077C (en) 2012-03-30 2020-09-29 Givaudan S.A. Powder flavour composition
KR102045589B1 (ko) 2012-03-30 2019-11-15 지보당 에스아 식품 향미 화합물로서의 n-아실-아미노산 유도체
WO2013149019A1 (en) 2012-03-30 2013-10-03 Givaudan S.A. N-acylated methionine derivatives as food flavouring compounds
CN104219965B (zh) 2012-03-30 2018-10-12 奇华顿股份有限公司 作为食品加香化合物的γ氨基-丁酸和β丙氨酸的N-酰基衍生物
EP2833739B1 (en) 2012-03-30 2020-12-02 Givaudan SA N-acyl proline derivatives as food flavouring compounds
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体
NZ707090A (en) * 2012-10-30 2019-03-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
WO2015050537A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
EP3057444B1 (en) 2013-10-02 2017-12-06 Givaudan SA Organic compounds having taste-modifying properties
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3057445B1 (en) 2013-10-02 2018-07-04 Givaudan SA Organic compounds having taste-modifying properties
CN105636459A (zh) 2013-10-02 2016-06-01 奇华顿股份有限公司 有机化合物
CN105592719B (zh) 2013-10-02 2020-03-10 奇华顿股份有限公司 有机化合物
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
FR2657259A1 (fr) 1991-07-26
FR2657259B1 (enExample) 1994-08-19
ES2060310T3 (es) 1994-11-16
CA2034861A1 (fr) 1991-07-26
ATE94387T1 (de) 1993-10-15
US5164414A (en) 1992-11-17
JPH0717503B2 (ja) 1995-03-01
DE69100364D1 (de) 1993-10-21
IE65573B1 (en) 1995-11-01
AU633395B2 (en) 1993-01-28
PT96571A (pt) 1991-10-15
IE910242A1 (en) 1991-07-31
AU6998791A (en) 1991-08-01
DE69100364T2 (de) 1994-04-21
EP0443891A1 (fr) 1991-08-28
EP0443891B1 (fr) 1993-09-15
DK0443891T3 (da) 1993-12-27
ZA91574B (en) 1991-11-27
JPH04210916A (ja) 1992-08-03

Similar Documents

Publication Publication Date Title
OA09478A (fr) "Utilisation de la N-myristoyl-(S)-phénylalaine pour l'obtention de médicaments destinés au traitement des maladies faisant intervenir la myristoylation".
OA07291A (fr) Gilet orthopédique de soutien et de contention dans le traitement des traumatisés et des opérés de l'épaule, de la ceinture scapulaire et du membre supérieur.
AU1808488A (en) Compounds for the treatment of alzheimer's disease
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
FR2617061B1 (fr) Pulverisateur portable de liquide, notamment pour le traitement de la vegetation
FR2662354B1 (fr) Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine.
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
OA09123A (fr) Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles.
EP0861082A4 (en) Tissue Membrane Insufficiency Therapy
BG94738A (bg) Използване на разтвор на йод за лечение на заболявания, свързани с йодна недостатъчност
NZ504419A (en) The use of carvedilol for treating amyloid diseases such as Alzheimer's
EP0270690A4 (en) MEDICINES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER AND KIDNEY DISEASES.
MD306B1 (ro) Remediu pentru profilaxia afectiunilor vasculare determinate de actiunea peroxizilor glicoproteinfixati
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
FR2717080B1 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FI852730A0 (fi) (pyrrol-1-yl) -fenyl-dihydropyridazinoner, deras framstaellning och anvaendning.
AU3709289A (en) Strontium salt
MC2246A1 (fr) Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
EP0687470A3 (en) Compounds for the treatment of metabolic bone diseases